A study of ethnic differences in TGFβ1 gene polymorphisms and effects on the risk of radiation pneumonitis in non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 7, Issue 11, 2012, Pages 1668-1675

  Niu, Xiaomin ^a   Li, Hongxuan ^a   Chen, Zhiwei ^a   Liu, Yun ^a,b,c   Kan, Mengyuan ^a,c   Zhou, Daizhan ^a,c   Li, Ziming ^a   Ye, Xiangyun ^a   Shen, Shengping ^a   Lv, Changxing ^a   Lu, Shun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c Chinese Academy of Sciences   (China)

Author keywords

Non small cell lung cancer; Radiation pneumonitis; Single nucleotide polymorphisms; Transforming growth factor beta 1

Indexed keywords

ADENINE; GUANINE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CAUCASIAN; CHEMORADIOTHERAPY; CHINESE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA ISOLATION; DNA POLYMORPHISM; DNA SEQUENCE; DOSIMETRY; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HAZARD RATIO; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE; RADIATION PNEUMONIA; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STATISTICAL SIGNIFICANCE;

EID: 84867900630     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318267cf5b     Document Type: Article

References (30)

1. Kim TH, Cho KH, Pyo HR, et al. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology 2005;235:208-215.
2. Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 2006;66:1399-1407.
3. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007;7:778-790.
4. Nieder C, Bremnes RM. Effects of smoking cessation on hypoxia and its potential impact on radiation treatment effects in lung cancer patients. Strahlenther Onkol 2008;184:605-609.
5. Jin H, Tucker SL, Liu HH, et al. Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with defnitive radiotherapy. Radiother Oncol 2009;91:427-432.
6. Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 2001;51:650-659.
7. Yorke ED, Jackson A, Rosenzweig KE, et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2002;54:329-339.
8. Tsujino K, Hirota S, Endo M, et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 2003;55:110-115.
9. Chang DT, Olivier KR, Morris CG, et al. The impact of heterogeneity correction on dosimetric parameters that predict for radiation pneumoni-tis. Int J Radiat Oncol Biol Phys 2006;65:125-131.
10. Tucker SL, Liu HH, Liao Z, et al. Analysis of radiation pneumonitis risk using a generalized Lyman model. Int J Radiat Oncol Biol Phys 2008;72:568-574.
11. Anscher MS, Garst J, Marks LB, et al. Assessing the ability of the anti-angiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. Int J Radiat Oncol Biol Phys 2006;66:477-482.
12. Barthelemy-Brichant N, Bosquée L, Cataldo D, et al. Increased IL-6 and TGF-beta1 concentrations in bronchoalveolar lavage fuid associated with thoracic radiotherapy. Int J Radiat Oncol Biol Phys 2004;58:758-767.
13. Kong FM, Hayman JA, Griffth KA, et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fbrosis. Int J Radiat Oncol Biol Phys 2006;65:1075-1086.
14. De Jaeger K, Seppenwoolde Y, Kampinga HH, Boersma LJ, Belderbos JS, Lebesque J V. Signifcance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;58:1378-1387.
15. De Jaeger K, Seppenwoolde Y, Lebesque J V, Kampinga HH. In response to Drs. Anscher and Kong. Int J Radiat Oncol Biol Phys 2005;63:308.
16. Kong FM, Ao X, Wang L, Lawrence TS. The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. Cancer Control 2008;15:140-150.
17. Yuan X, Liao Z, Liu Z, et al. Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with defnitive radiotherapy. J Clin Oncol 2009;27:3370-3378.
18. Wang L, Bi N. TGF-beta1 gene polymorphisms for anticipating radiation-induced pneumonitis in non-small-cell lung cancer: different ethnic association. J Clin Oncol 2010;28:e621-e622.
19. Goldstraw P, Crowley J, Chansky K, et al.; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classifcation of malignant tumours. J Thorac Oncol 2007;2:706-714.
20. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-181.
21. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005;15:97-98.
22. Novakova-Jiresova A, Van Gameren MM, Coppes RP, Kampinga HH, Groen HJ. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother Oncol 2004;71:183-189.
23. Barcellos-Hoff MH. How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. Radiat Res 1998;150(5 Suppl):S109-S120.
24. Martin M, Lefaix J, Delanian S. TGF-beta1 and radiation fbrosis: a master switch and a specifc therapeutic target? Int J Radiat Oncol Biol Phys 2000;47:277-290.
25. Anscher MS, Thrasher B, Rabbani Z, Teicher B, Vujaskovic Z. Antitransforming growth factor-beta antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation. Int J Radiat Oncol Biol Phys 2006;65:876-881.
26. Kong FM, Washington MK, Jirtle RL, Anscher MS. Plasma transforming growth factor-beta 1 refects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer 1996;16:47-59.
27. Blobe GC, Schiemann W P, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350-1358.
28. Haukim N, Bidwell JL, Smith AJ, et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun 2002;3:313-330.
29. Saltzman BS, Yamamoto JF, Decker R, et al. Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neoplasia. Cancer Res 2008;68:1236-1244.
30. Inoue A, Kunitoh H, Sekine I, Sumi M, Tokuuye K, Saijo N. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys 2001;49:649-655.